|

ARV-393 Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Phase 1: 1

Top Sponsors

  • Arvinas Inc.1

Indications

  • Relapsed/Refractory (R/R) Angioimmunoblastic T-cell Lymphoma (AITL)1
  • Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL)1
  • Cancer1

New Haven, Connecticut1 trial

A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.

Clinical Trial Site

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.